American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Clinical and Neuropathological Aspects of Chronic Herpetic Encephalitis: An In-Depth Review

Hakimova Sokhiba Ziyadullovna
Samarkand State Medical University

Gaffarova Parvina Abdurafikovna
Samarkand State Medical University

Zayniyev Muzaffarjon Xurshedjon ugli
Samarkand State Medical University

Received: 2025 01, Oct
Accepted: 2025 15, Oct
Published: 2025 20, Oct

Annotation: Chronic herpetic encephalitis (CHE) is a rare, slowly progressing inflammatory disease of the central nervous system (CNS), caused by the persistent presence of herpes simplex virus type 1 (HSV-1) in neural tissue. Unlike acute herpetic encephalitis, the chronic form manifests with long-term neurological impairment, mimicking degenerative and autoimmune diseases. This paper aims to explore the pathogenesis, clinical features, diagnostic approaches, imaging findings, therapeutic strategies, and prognosis of CHE. Given its insidious onset and diagnostic difficulty, awareness of this condition is critical among neurologists and infectious disease specialists to avoid underrecognition and mistreatment.

Keywords: Chronic herpetic encephalitis, HSV-1, neuroinflammation, temporal lobe, cognitive impairment, antiviral therapy, CNS infection.

INTRODUCTION

Herpes simplex virus type 1 (HSV-1) is a highly prevalent neurotropic pathogen responsible for a wide range of neurological and mucocutaneous diseases. While the clinical features of acute HSV encephalitis are well established, its chronic counterpart—chronic herpetic encephalitis (CHE)—remains poorly characterized due to its rarity and diagnostic complexity. CHE typically develops in immunocompromised hosts or in individuals who fail to achieve complete viral clearance following an acute encephalitic episode.

Epidemiology and Viral Persistence

Epidemiological evidence demonstrates that HSV-1 establishes latency in sensory ganglia, particularly the trigeminal and olfactory ganglia, where it can persist lifelong. Reactivation may occur under specific conditions that favor viral replication, such as immunosuppression or physiological stress. Chronic infection is characterized by low-grade inflammation, ongoing neuronal apoptosis, and gradual neurodegeneration, underscoring the virus's ability to subtly disrupt central nervous system (CNS) integrity over time.

Pathogenesis and Neuropathology

The pathophysiological mechanisms underlying CHE are thought to involve either reactivation of latent HSV-1 within the CNS or incomplete viral clearance following an acute infection. Even when viral replication is minimal, persistent immune activation drives gliosis, demyelination, and progressive neuronal loss. Neuropathological changes predominantly affect the medial temporal lobes and orbitofrontal cortex, regions vital for cognition, memory, and emotional processing.

Immunopathology

The immune response in CHE plays a paradoxical role. While it limits viral replication, chronic activation of microglia and astrocytes perpetuates neuroinflammation and contributes to secondary neuronal damage. Cerebrospinal fluid (CSF) analyses frequently reveal elevated proinflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). This cytokine milieu reflects ongoing immune dysregulation and correlates with disease severity.

Clinical Manifestations

CHE develops insidiously, with symptoms progressing over months or years. Typical features include:

- Progressive cognitive decline and memory impairment
- Personality and behavioral alterations
- Recurrent focal or generalized seizures
- Hemiparesis or aphasia
- Psychiatric symptoms such as depression or psychosis

The clinical profile often mimics neurodegenerative disorders, particularly Alzheimer's disease and frontotemporal dementia, leading to diagnostic delays. In pediatric patients, developmental regression and behavioral abnormalities are more common, whereas adults tend to exhibit progressive amnesia and seizure recurrence.

Diagnostic Evaluation

Neuroimaging

Magnetic resonance imaging (MRI) is a cornerstone in diagnosing CHE. T2-weighted and

FLAIR sequences typically reveal hyperintense lesions within the temporal lobes. In advanced cases, cerebral atrophy and ventricular dilation may also be observed.

Cerebrospinal Fluid (CSF) Analysis and PCR

CSF findings usually show mild pleocytosis, elevated protein, and normal glucose levels. Detection of HSV-1 DNA via polymerase chain reaction (PCR) remains the gold standard for diagnosis; however, low viral loads in chronic disease may yield false-negative results, complicating diagnostic accuracy.

Electroencephalography (EEG) and Brain Biopsy

EEG often demonstrates periodic lateralized epileptiform discharges (PLEDs). In diagnostically challenging cases, brain biopsy provides definitive confirmation. Histopathological analysis typically reveals gliosis, neuronal necrosis, and HSV-1 antigens within affected tissues.

Differential Diagnosis

CHE should be differentiated from several conditions with overlapping clinical and radiological features, including:

- Autoimmune limbic encephalitis
- Alzheimer's disease
- Subacute sclerosing panencephalitis (SSPE)
- Progressive multifocal leukoencephalopathy (PML)
- Neurosarcoidosis

Comprehensive serological testing and autoimmune antibody panels are essential for accurate exclusion of mimicking disorders.

Treatment Approaches

Antiviral Therapy

Prolonged antiviral treatment remains the mainstay of management. High-dose acyclovir (10 mg/kg every 8 hours for 21–28 days) or oral valacyclovir is typically administered. In recurrent or persistent cases, repeated or extended treatment courses may be required to achieve viral suppression.

Adjunctive Immunomodulation

Corticosteroids may be considered in patients exhibiting significant inflammatory activity, particularly in steroid-responsive variants. In select immune-mediated presentations, intravenous immunoglobulin (IVIG) or plasmapheresis may serve as valuable adjuncts to therapy.

Supportive and Rehabilitative Care

Comprehensive rehabilitation is often necessary to manage cognitive, behavioral, and motor deficits. This includes neuropsychological therapy, antiepileptic management, and multidisciplinary rehabilitation programs, all of which are crucial for improving long-term functional outcomes.

Prognosis

The prognosis of CHE varies widely, depending on the timeliness of diagnosis and initiation of therapy. Early recognition and treatment can result in substantial neurological recovery, while delayed management often leads to irreversible cognitive and motor impairment. Recurrence is particularly common in immunocompromised individuals, necessitating ongoing clinical surveillance and long-term antiviral prophylaxis in selected cases.

Conclusion

Although rare, chronic herpetic encephalitis should be considered in patients presenting with progressive neurocognitive decline, especially those with prior HSV-1 infection or temporal lobe abnormalities on MRI. Prompt initiation of antiviral and, when appropriate, immunomodulatory

therapy can significantly alter disease trajectory and improve neurological outcomes. Continued research is needed to identify reliable biomarkers for early detection and to develop targeted therapeutic strategies aimed at preventing irreversible CNS damage.

REFERENCE

1. Armangué, T., Olivé-Cirera, G., Martínez-Hernandez, E., Rodes, M., Peris-Sempere, V., Guasp, M., ... & Dalmau, J. (2023). Neurologic complications in herpes simplex encephalitis: clinical, immunological and genetic studies. Brain, 146(10), 4306-4319.
2. Hussain, M. S., Gupta, G., Samuel, V. P., Almalki, W. H., Kazmi, I., Alzarea, S. I., ... & Dua, K. (2024). Immunopathology of herpes simplex virus-associated neuroinflammation: Unveiling the mysteries. Reviews in medical virology, 34(1), e2491.
3. Arciniegas, D. B., & Anderson, C. A. (2004). Viral encephalitis: neuropsychiatric and neurobehavioral aspects. Current Psychiatry Reports, 6(5), 372-379.
4. Petito, C. K., Cho, E. S., Lemann, W., Navia, B. A., & Price, R. W. (1986). Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. Journal of Neuropathology & Experimental Neurology, 45(6), 635-646.
5. Сохиба, Х., Бахора, Х., & Муродуллаева, П. (2025). Роль Ликвородинамических Нарушений У Больных С Хронической Ишемией Головного Мозга (ДЭ). world of Medicine: Journal of Biomedical Sciences, 2(1), 220-225.
6. Sili, U., Kaya, A., Mert, A., & HSV Encephalitis Study Group. (2014). Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients. Journal of Clinical Virology, 60(2), 112-118.
7. Ludlow, M., Kortekaas, J., Herden, C., Hoffmann, B., Tappe, D., Trebst, C., ... & Osterhaus, A. D. (2016). Neurotropic virus infections as the cause of immediate and delayed neuropathology. Acta neuropathologica, 131, 159-184.
8. Tunkel AR, Glaser CA, Bloch KC, et al. The Management of Encephalitis: Clinical Practice Guidelines. Clin Infect Dis. 2008.
9. Кудашев, Н. И., Сухих, Г. Т., Файзуллин, Л. З., & Александровский, А. В. (2015). Герпесвирусная инфекция. Диагностика и терапия тяжелых форм у новорожденных. Общество с ограниченной ответственностью «Издательство «Литтерра».
10. Whitley RJ. Herpes Simplex Encephalitis: Adolescents and Adults. Antiviral Res. 2006